AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.
By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...
Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies ...
AstraZeneca makes proposals to cut U.S. drug price cuts CEO Soriot says also considering direct sales to customers AstraZeneca maintains annual outlook Second-quarter sales and profit beat analysts' ...
Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results